December 21, 2013

Use of phosphate-binding agents is associated with a lower risk of mortality

.   .   

In this mulitcenter, observational, prospective study of stage 5 CKD patients on dialysis, the use of phosphate-binding agents was shown to lower all-cause and cardiovascular mortality by 29% and 22% respectively. All agents proved to be beneficial except aluminum salts. There interesting findings need to be confirmed in randomized clinical trials.

Related Articles:

Bone Mineral Metabolism, Chronic Kidney Disease, Clinical Nephrology, Hemodialysis

Comments are closed.